CSF3 and plasma cell myeloma: The aim of this study has been to assess the efficacy and the safety of biosimilar Peg-Filgrastim among a lymphoma and myeloma patient population undergoing ASCT, comparing these data with those derived by our historical control groups of patients receiving other G-CSFs for febrile neutropenia prophylaxis (i.e., biosimilar Filgrastim, originator Peg-filgrastim, and Lenograstim).